Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
62 400
214 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sam Chun Dang Pharm Co Ltd
Total Other Income
Sam Chun Dang Pharm Co Ltd
Total Other Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Total Other Income
-₩21.4m
|
CAGR 3-Years
79%
|
CAGR 5-Years
24%
|
CAGR 10-Years
43%
|
|
|
Yuhan Corp
KRX:000100
|
Total Other Income
-₩5B
|
CAGR 3-Years
40%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-21%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Total Other Income
-₩138.9m
|
CAGR 3-Years
37%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Total Other Income
-₩1.8B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Total Other Income
-₩4.3B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Total Other Income
-₩179.8m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Sam Chun Dang Pharm Co Ltd
Glance View
SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2000-10-04. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Company’s products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.
See Also
What is Sam Chun Dang Pharm Co Ltd's Total Other Income?
Total Other Income
-21.4m
KRW
Based on the financial report for Sep 30, 2024, Sam Chun Dang Pharm Co Ltd's Total Other Income amounts to -21.4m KRW.
What is Sam Chun Dang Pharm Co Ltd's Total Other Income growth rate?
Total Other Income CAGR 10Y
43%
Over the last year, the Total Other Income growth was -285%. The average annual Total Other Income growth rates for Sam Chun Dang Pharm Co Ltd have been 79% over the past three years , 24% over the past five years , and 43% over the past ten years .
You don't have any saved screeners yet
